非诺贝特治疗慢性肾病合并高脂血症的效果观察  

Effect of fenofibrate on chronic kidney disease with hyperlipidemia

作　　者：张冕[1] 宋国巍[1] 桑大华[1] 孙亮[1] 王磊[1] Zhang Mian;Song Guowei;Sang Dahua;Sun Liang;Wang Lei(Department of Nephrology,Jilin Province People's Hospital,Changchun 130021,China)

机构地区：[1]吉林省人民医院肾内科,吉林省长春市130021

出　　处：《现代养生》2023年第19期1464-1468,共5页Health Protection and Promotion

基　　金：吉林省卫生健康科技能力提升项目(编号:2017Q006)。

摘　　要：目的观察在常规治疗基础上联合应用非诺贝特治疗慢性肾脏病合并高脂血症患者的临床疗效。方法将2020年1月-2022年12月吉林省人民医院收治的慢性肾病合并高脂血症患者作为研究对象,选择联合应用非诺贝特治疗的24例患者为观察组(非诺贝特组),根据组间性别、年龄、体质量指数(BMI)、病程等基线资料均衡可比的原则,同期选择其中采用常规治疗的24例患者为对照组(常规组)。两组患者常规治疗相同,非诺贝特组在常规治疗的基础上给予非诺贝特胶囊,治疗8周后观察两组患者症状及蛋白尿的改善情况,对两组患者治疗前后血脂[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、24h尿蛋白定量(M-TP)、血清白蛋白(Alb)、肝功能指标[丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)]、肾功能指标[肌酐(CRE)、尿素氮(BUN)]以及血清C反应蛋白(CRP)、纤维蛋白原(FG)等水平进行比较。结果经过治疗,非诺贝特组患者治疗的总有效率为91.67%,高于常规治疗组的58.33%,差异有统计学意义(P<0.05)。治疗前,两组患者TC、TG、LDL-C、HDL-C、ALT、AST、CRE、BUN、M-TP、Alb、CRP及FG水平比较差异均无统计学意义(P>0.05);治疗后,两组患者上述指标均有改善,组间比较,非诺贝特治疗组患者TG、CRE、M-TP及CRP水平均低于常规治疗组,而Alb水平显著高于常规治疗组,组间差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论非诺贝特可有效改善慢性肾病合并高脂血症患者的肾功能,可能与其具有较好的降脂作用以及抗炎、凝血-纤溶系统调节作用有关。Objective To observe the clinical efficacy of fenofibrate combined with conventional treatment in the treatment of chronic kidney disease patients with hyperlipidemia.Methods The patients with chronic kidney disease and hyperlipidemia admitted to Jilin Provincial People's Hospital from January 2020 to December 2022 were taken as the research objects.24 patients who were treated with fenofibrate in combination were selected as the observation group(fenofibrate group).According to the principle of balanced and comparable baseline data such as gender,age,body mass index(BMI),and course of disease,24 patients who were treated with conventional therapy were selected as the control group(conventional group)at the same time.The routine treatment of the patients in the two groups was the same.The fenofibrate group was given fenofibrate capsules on the basis of routine treatment.After 8 weeks of treatment,the symptoms and improvement of proteinuria of the patients in the two groups were observed.The blood lipids[total cholesterol(TC),triacylglycerol(TG),low density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],24-hour urinary protein quantification(M-TP),serum albumin(Alb),the liver function indexes[alanine aminotransferase(ALT),asparagus cochinchinensis aminotransferase(AST)],renal function indexes[creatinine(CRE),blood urea nitrogen(BUN)],serum C-reactive protein(CRP),fibrinogen(FG)and other levels were compared.Results After treatment,the total effective rate of patients in the fenofibrate group was 91.67%,higher than 58.33% in the conventional treatment group,with a statistically significant difference(P<0.05).Before treatment,there was no statistically significant difference in the levels of TC,TG,LDL-C,HDL-C,ALT,AST,CRE,BUN,M-TP,Alb,CRP,and FG between the two groups of patients(P>0.05).After treatment,the above indicators of the two groups of patients were improved.Compared with each other,the levels of TG,CRE,M-TP and CRP of patients in the fenofibrate treatment group were lower than t

关 键 词：慢性肾病 高血脂 非诺贝特 临床疗效 不良反应 

分 类 号：R692[医药卫生—泌尿科学]